Skip to main content
Premium Trial:

Request an Annual Quote

Torus Biosystems Completes $25M Series A Financing Round

NEW YORK – Torus Biosystems announced on Wednesday the completion of a $25 million Series A financing round. The firm will use the funding to accelerate commercialization of its point-of-care syndromic testing system, Synestia.

The financing round was led by Northpond Ventures. Prior investors, including Torus cofounder David Walt, also participated in the round. Northpond's director Adam Wieschhaus will join Torus' board.

Synestia is a sample-to-answer molecular diagnostic system that can detect multiple targets in 30 minutes using proprietary probes, nanoarrays, and convection qPCR. The firm is developing assays for the identification of infectious disease pathogens, host immune response, and drug resistance.

"Our goal is to provide the healthcare system with a new gold standard in syndromic testing, including a broad menu of tests on a compact, portable device that delivers rapid results when providers need them to make the best clinical decisions for their patients," said Shawn Marcell, Torus' cofounder and CEO, in a statement.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.